IL140592A0 - Synthetic peptides and methods of use for autoimmune disease therapies - Google Patents
Synthetic peptides and methods of use for autoimmune disease therapiesInfo
- Publication number
- IL140592A0 IL140592A0 IL14059299A IL14059299A IL140592A0 IL 140592 A0 IL140592 A0 IL 140592A0 IL 14059299 A IL14059299 A IL 14059299A IL 14059299 A IL14059299 A IL 14059299A IL 140592 A0 IL140592 A0 IL 140592A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- autoimmune disease
- synthetic peptides
- disease therapies
- therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9385998P | 1998-07-23 | 1998-07-23 | |
US12367599P | 1999-03-09 | 1999-03-09 | |
PCT/US1999/016617 WO2000005249A2 (fr) | 1998-07-23 | 1999-07-22 | Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes |
Publications (1)
Publication Number | Publication Date |
---|---|
IL140592A0 true IL140592A0 (en) | 2002-02-10 |
Family
ID=26787981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14059299A IL140592A0 (en) | 1998-07-23 | 1999-07-22 | Synthetic peptides and methods of use for autoimmune disease therapies |
Country Status (8)
Country | Link |
---|---|
US (2) | US7566767B2 (fr) |
EP (3) | EP1105414A2 (fr) |
JP (1) | JP2003521448A (fr) |
AU (1) | AU766498B2 (fr) |
CA (1) | CA2336238A1 (fr) |
IL (1) | IL140592A0 (fr) |
WO (1) | WO2000005249A2 (fr) |
ZA (1) | ZA200100366B (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
AU766498B2 (en) * | 1998-07-23 | 2003-10-16 | President And Fellows Of Harvard College, The | Synthetic peptides and methods of use for autoimmune disease therapies |
CA2337688C (fr) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Traitement de maladies auto-immunes a l'aide du copolymere 1 et copolymeres associes |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
WO2005046719A1 (fr) | 2003-11-12 | 2005-05-26 | Yeda Research And Development Co. Ltd. | Vaccin et procede pour traiter des maladies neurodegeneratives |
US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (fr) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere |
AU2002362445B2 (en) | 2001-10-03 | 2006-09-21 | President And Fellows Of Harvard College | Copolymers for suppression of autoimmune diseases, and methods of use |
ES2349033T3 (es) | 2001-12-04 | 2010-12-22 | Teva Pharmaceutical Industries, Ltd. | Procedimientos para la medida de la actividad del acetato de glatiramer. |
MXPA04005537A (es) | 2001-12-06 | 2004-11-01 | Yeda Res & Dev | Vacuna y metodo para el tratamiento de enfermedades de las neuronas motoras. |
DE60320196T2 (de) * | 2002-10-02 | 2009-05-14 | F. Hoffmann-La Roche Ag | Verfahren zur Identifizierung antigener Peptide |
NZ569331A (en) * | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
CA2548310C (fr) | 2003-12-09 | 2014-02-18 | Yeda Research And Development Co. Ltd. | Methode et vaccin comprenant le copolymere 1 pour le traitement de troubles psychiatriques |
US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
BRPI0510738A (pt) | 2004-05-07 | 2007-11-20 | Peptimmune Inc | métodos de tratar doenças com copolìmeros aleatórios |
SI1797109T1 (sl) * | 2004-09-09 | 2016-07-29 | Yeda Research And Development Co., Ltd. | Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe |
US20070264229A1 (en) * | 2004-09-13 | 2007-11-15 | Strominger Jack L | Peptides for Treatment of Autoimmune Disease |
EP1853287A2 (fr) * | 2005-02-02 | 2007-11-14 | Yeda Research And Development Co., Ltd. | Copolymeres peptidiques synthetiques pour le traitement et la prevention de troubles cardiovasculaires |
AU2007238595A1 (en) | 2006-04-13 | 2007-10-25 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
WO2008001380A2 (fr) | 2006-06-28 | 2008-01-03 | Yeda Research And Development Co. Ltd. | Méthode de traitement de la dégénérescence maculaire liée à l'âge |
WO2009018477A2 (fr) * | 2007-07-31 | 2009-02-05 | Cognosci, Inc. | Procédés d'inhibition de la calcineurine avec des analogues d'apoe |
BRPI0817682A2 (pt) | 2007-10-16 | 2015-04-07 | Peptimmune Inc | Métodos para projetar e preparar vacinas compreendendo composições de polímero de sequência direcionada via a expansão direta de epítopos |
CA2760802C (fr) | 2009-08-20 | 2016-01-12 | Ety Klinger | Therapie a l'acetate de glatiramere a basse frequence |
JP2013511725A (ja) * | 2009-11-17 | 2013-04-04 | アレス トレーディング ソシエテ アノニム | 血清タンパク質に基づくランダム配列ポリマー組成物の検出による、ランダム配列ポリマー組成物の設計、生物学的利用性、及び有効性を改良するための方法 |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
NZ703122A (en) | 2010-10-11 | 2016-06-24 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
EP2667888A4 (fr) * | 2011-01-28 | 2015-11-11 | Univ Oregon Health & Science | Ligands des lymphocytes t recombinés et anticorps se liant aux lymphocytes b destinés au traitement de maladies autoimmunes |
WO2013055683A1 (fr) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Polymorphismes de nucléotide simple utiles pour prédire une réponse clinique à l'acétate de glatiramère |
US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
AU2015228372B2 (en) | 2014-03-12 | 2018-05-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
JP2017525370A (ja) | 2014-08-21 | 2017-09-07 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインを調製および使用する方法 |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
CA3050086A1 (fr) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Systemes de depot de glatiramere pour le traitement de formes progressives de sclerose en plaques |
WO2019175869A1 (fr) | 2018-03-12 | 2019-09-19 | Yeda Research And Development Co. Ltd | Traitement d'une maladie cardiaque |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
US6066621A (en) | 1989-12-10 | 2000-05-23 | Yeda Research And Development Co. Ltd. | Synthetic peptides for the treatment of myasthenia gravis |
WO1992002543A1 (fr) * | 1990-08-01 | 1992-02-20 | Cytel Corporation | Nouveaux peptides immunosuppresseurs |
US5679640A (en) * | 1991-02-12 | 1997-10-21 | Cytel Corporation | Immunosuppressant peptides |
US5583031A (en) | 1992-02-06 | 1996-12-10 | President And Fellows Of Harvard College | Empty major histocompatibility class II heterodimers |
WO1994000148A1 (fr) | 1992-06-18 | 1994-01-06 | Yeda Research And Development Co. Ltd. | Peptides synthetiques pour le traitement de la myasthenie grave |
US6696061B1 (en) | 1992-08-11 | 2004-02-24 | President And Fellows Of Harvard College | Immunomodulatory peptides |
AU6916694A (en) * | 1993-05-19 | 1994-12-12 | Cytel Corporation | Novel treatments for allergic diseases |
US5576419A (en) * | 1993-06-30 | 1996-11-19 | Regents Of The University Of Minnesota | Mild solid-phase synthesis of aligned branched triple-helical peptides |
AU698962B2 (en) | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
WO1995026980A2 (fr) * | 1994-04-01 | 1995-10-12 | Immulogic Pharmaceutical Corporation | Peptides haptines et leurs utilisations |
AU7242994A (en) * | 1994-05-20 | 1995-12-18 | United States Of America, As Represented By The Secretary Of The Army, The | Model for testing immunogenicity of peptides |
US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
US5858964A (en) | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
WO1997049430A1 (fr) | 1996-06-26 | 1997-12-31 | Antigen Express, Inc. | Immunotherapie par modulation de la presentation d'antigenes |
WO1998005684A2 (fr) | 1996-08-05 | 1998-02-12 | President And Fellows Of Havard College | Oligomeres peptidiques de liaison cmh et procedes d'utilisation |
IL119989A0 (en) * | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
CA2337688C (fr) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Traitement de maladies auto-immunes a l'aide du copolymere 1 et copolymeres associes |
AU766498B2 (en) * | 1998-07-23 | 2003-10-16 | President And Fellows Of Harvard College, The | Synthetic peptides and methods of use for autoimmune disease therapies |
US6514938B1 (en) * | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6844314B2 (en) * | 2000-01-20 | 2005-01-18 | Yeda Research Development Co., Ltd. | Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
AU2002362445B2 (en) * | 2001-10-03 | 2006-09-21 | President And Fellows Of Harvard College | Copolymers for suppression of autoimmune diseases, and methods of use |
US20060276390A1 (en) * | 2003-07-31 | 2006-12-07 | Yeda Research And Development Co. Ltd. | Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
-
1999
- 1999-07-22 AU AU52234/99A patent/AU766498B2/en not_active Ceased
- 1999-07-22 IL IL14059299A patent/IL140592A0/xx unknown
- 1999-07-22 EP EP19990937393 patent/EP1105414A2/fr not_active Withdrawn
- 1999-07-22 JP JP2000561205A patent/JP2003521448A/ja active Pending
- 1999-07-22 WO PCT/US1999/016617 patent/WO2000005249A2/fr not_active Application Discontinuation
- 1999-07-22 CA CA 2336238 patent/CA2336238A1/fr not_active Abandoned
- 1999-07-23 EP EP20100180952 patent/EP2327712B1/fr not_active Expired - Lifetime
- 1999-07-23 EP EP20140188800 patent/EP2848627A3/fr not_active Withdrawn
-
2001
- 2001-01-12 ZA ZA200100366A patent/ZA200100366B/en unknown
-
2003
- 2003-05-15 US US10/438,538 patent/US7566767B2/en not_active Expired - Fee Related
-
2008
- 2008-01-09 US US12/008,250 patent/US9066905B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2000005249A3 (fr) | 2000-10-05 |
EP2327712B1 (fr) | 2014-10-15 |
ZA200100366B (en) | 2002-01-14 |
EP1105414A2 (fr) | 2001-06-13 |
EP2327712A3 (fr) | 2011-09-14 |
AU766498B2 (en) | 2003-10-16 |
US20080207526A1 (en) | 2008-08-28 |
JP2003521448A (ja) | 2003-07-15 |
CA2336238A1 (fr) | 2000-02-03 |
EP2327712A2 (fr) | 2011-06-01 |
WO2000005249A2 (fr) | 2000-02-03 |
US20040006022A1 (en) | 2004-01-08 |
US9066905B2 (en) | 2015-06-30 |
EP2848627A3 (fr) | 2015-04-01 |
EP2848627A2 (fr) | 2015-03-18 |
AU5223499A (en) | 2000-02-14 |
US7566767B2 (en) | 2009-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL140592A0 (en) | Synthetic peptides and methods of use for autoimmune disease therapies | |
HUP0103321A3 (en) | Peptide antagonists of zonulin and methods for use of the same | |
EP0880356A4 (fr) | Peptides antimicrobiens et procedes d'utilisation associes | |
EP0785276A4 (fr) | Modification d'un peptide et d'une proteine | |
HK1096974A1 (en) | Antibody against human parathormone related peptides | |
ZA969444B (en) | Peptides which enhance transport across tissues and methods of identifying and using the same | |
EP1037911A4 (fr) | Systeme anti-pathogene et procedes d'utilisation | |
IL112903A0 (en) | GnRH antagonist peptides | |
EP1071706A4 (fr) | Proteines de fusion gfp a degradation rapide et methodes d'utilisation | |
HUP9903378A3 (en) | Autoantigen and proteins structurally related thereto for use in immunotherapy of autoimmune diseases | |
EP0831793A4 (fr) | Particules proteiques a usage therapeutique et diagnostique | |
HUP9900147A3 (en) | Therapeutic agents and autoimmune diseases | |
IL129024A0 (en) | Use of proteins as agent against autoimmune diseases | |
IL131929A0 (en) | Rap protein its preparation and use | |
HUP9801680A3 (en) | Peptides and remedy for autoimmune diseases comprising the same | |
AU1087797A (en) | Clip analogues and autoimmune disease | |
GB9918155D0 (en) | Proteins and peptides | |
EP1046036A4 (fr) | Procedes d'obtention de sondes de fonction de peptides | |
GB9621825D0 (en) | Microparticles and their use as therapeutic vehicles | |
IL120759A0 (en) | Modulators of the function of fas receptors and other proteins | |
AU4705201A (en) | Peptide constructs for treating autoimmune and related diseases | |
AU3964499A (en) | Agouti-related protein analogs and methods of use | |
EP1119251A4 (fr) | Procedes de detection d'agents regulant l'apoptose destines a la therapie anabolisante osseuse et utilisations de tels agents | |
GB9714276D0 (en) | Peptides and related compounds | |
IL116658A0 (en) | Peptides their preparation and use |